Latest Insider Transactions at Biovie Inc. (BIVI)
This section provides a real-time view of insider transactions for Biovie Inc. (BIVI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOVIE INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOVIE INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Cuong V Do President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
42,000
-7.07%
|
$0
$0.47 P/Share
|
|
Jun 24
2024
|
Cuong V Do President & CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
168,000
+22.05%
|
-
|
|
Jun 24
2024
|
Joanne Wendy Kim Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,250
-16.27%
|
$0
$0.47 P/Share
|
|
Jun 24
2024
|
Joanne Wendy Kim Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,000
+39.42%
|
-
|
|
Jun 24
2024
|
Joseph M Palumbo Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,000
-19.57%
|
$0
$0.47 P/Share
|
|
Jun 24
2024
|
Joseph M Palumbo Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
116,000
+43.91%
|
-
|
|
Mar 04
2024
|
Cuong V Do President & CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+2.24%
|
-
|
|
Feb 15
2024
|
Cuong V Do President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,953
-1.15%
|
$4,953
$1.18 P/Share
|
|
Feb 15
2024
|
Joanne Wendy Kim Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-5.94%
|
$2,476
$1.18 P/Share
|
|
Feb 15
2024
|
Joseph M Palumbo Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-7.14%
|
$2,476
$1.18 P/Share
|
|
Dec 11
2023
|
Joanne Wendy Kim Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.17%
|
-
|
|
Dec 01
2023
|
Steve Gorlin Director |
SELL
Open market or private sale
|
Direct |
75,680
-62.01%
|
$75,680
$1.69 P/Share
|
|
Nov 30
2023
|
Cuong V Do President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+12.7%
|
$10,000
$1.78 P/Share
|
|
Nov 09
2023
|
Richard J Berman Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,830
+42.81%
|
-
|
|
Nov 09
2023
|
Robert J Hariri Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,254
+50.0%
|
-
|
|
Nov 09
2023
|
Sigmund Rogich Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,254
+50.0%
|
-
|
|
Nov 09
2023
|
Steve Gorlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
46,358
+27.53%
|
-
|
|
Sep 05
2023
|
Steve Gorlin Director |
SELL
Open market or private sale
|
Direct |
8,560
-10.16%
|
$25,680
$3.05 P/Share
|
|
Aug 22
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
10,805
-39.16%
|
$32,415
$3.5 P/Share
|
|
Jun 29
2023
|
Cuong V Do President & CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
149,500
+25.98%
|
-
|
|
Jun 21
2023
|
Cuong V Do President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,506
+13.26%
|
-
|
|
Jun 07
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
5,984
-20.5%
|
$29,920
$5.81 P/Share
|
|
May 22
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
5,000
-14.62%
|
$30,000
$6.5 P/Share
|
|
Mar 28
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
7,613
-9.53%
|
$60,904
$8.52 P/Share
|
|
Mar 27
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
3,371
-7.46%
|
$26,968
$8.52 P/Share
|
|
Feb 16
2023
|
Cuong V Do President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
9,906
-1.62%
|
$49,530
$5.82 P/Share
|
|
Feb 16
2023
|
Joanne Wendy Kim Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,952
-5.78%
|
$24,760
$5.82 P/Share
|
|
Feb 16
2023
|
Joseph M Palumbo Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,952
-6.46%
|
$24,760
$5.82 P/Share
|
|
Feb 16
2023
|
Clarence N. Ahlem EVP Neuroscience Product Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Penelope Markham EVP Liver Cirrhosis R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-4.92%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Christopher Reading EVP Neuroscience R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|
|
Nov 23
2022
|
Steve Gorlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,240
+28.9%
|
-
|
|
Nov 23
2022
|
James Paul Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,578
+38.84%
|
-
|
|
Nov 23
2022
|
Penelope Markham EVP Liver Cirrhosis R&D |
BUY
Grant, award, or other acquisition
|
Direct |
39,624
+44.06%
|
-
|
|
Nov 23
2022
|
Cuong V Do President & CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
79,248
+25.23%
|
-
|
|
Nov 23
2022
|
Joanne Wendy Kim Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,624
+48.77%
|
-
|
|
Nov 23
2022
|
Richard J Berman Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,578
+49.1%
|
-
|
|
Nov 23
2022
|
Clarence N. Ahlem EVP Neuroscience Product Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
39,624
+50.0%
|
-
|
|
Nov 23
2022
|
Joseph M Palumbo Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,624
+50.0%
|
-
|
|
Nov 23
2022
|
Robert J Hariri Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,240
+50.0%
|
-
|
|
Nov 23
2022
|
Christopher Reading EVP Neuroscience R&D |
BUY
Grant, award, or other acquisition
|
Direct |
39,624
+50.0%
|
-
|
|
Aug 15
2022
|
Terren S Peizer Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,636,364
+13.57%
|
$3,636,364
$1.65 P/Share
|
|
Feb 02
2022
|
Jonathan M Adams EVP Liver Cirrhosis Programs |
SELL
Bona fide gift
|
Direct |
1,000
-2.01%
|
-
|
|
Dec 31
2021
|
Cuong V Do President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
21,710
+26.98%
|
-
|
|
Dec 07
2021
|
Joanne Wendy Kim Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$10,000
$5.4 P/Share
|
|
Jun 16
2021
|
Jonathan M Adams EVP Liver Cirrhosis Programs |
SELL
Bona fide gift
|
Direct |
10,000
-16.77%
|
-
|
|
Jun 10
2021
|
Terren S Peizer Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,361,308
+29.98%
|
-
|
|
Nov 03
2020
|
Steve Gorlin Director |
BUY
Open market or private purchase
|
Direct |
2,430
+5.11%
|
$17,010
$7.95 P/Share
|
|
Oct 30
2020
|
Steve Gorlin Director |
BUY
Open market or private purchase
|
Direct |
2,570
+5.68%
|
$17,990
$7.97 P/Share
|
|
Oct 21
2020
|
Steve Gorlin Director |
BUY
Open market or private purchase
|
Direct |
5,000
+11.09%
|
$45,000
$9.19 P/Share
|